Clearmind Medicine Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adi Zuloff-Shani
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1220 West 6th Avenue Vancouver BC Canada V6H 1A5
- IPO Date
- Nov 15, 2022
- CIK
- 0001892500
- Website
- clearmindmedicine.com
- Similar Companies
- Business
- Clearmind Medicine Inc. is a clinical-stage pharmaceutical company that develops novel psychedelic-derived medicines aimed at treating widespread and under-served health problems. The company’s core product offerings include psychedelic-based therapeutics targeting alcohol use disorders, binge drinking, eating disorders, weight loss, obesity, metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment-resistant depression. Its key products under development are the MEAI compound for treating alcohol use disorder, obesity, and metabolic disorders, including an alcohol substitute consumer product, and CM-CMND-001, currently in Phase I/IIa clinical trials for alcohol use disorder treatment. The company also explores combination treatments for obesity and metabolic syndrome through collaborations. Recent major changes include a strategic partnership with Dr. Glitter Pty Ltd to co-develop and commercialize an MEAI-based alcohol substitute using Dr. Glitter’s ActivCrystal™ technology, an innovative oral delivery format that enables flexible consumption by sprinkling the product onto food or beverages. This partnership aims to provide a safer alternative to traditional alcohol consumption, addressing alcohol misuse and related health risks. Additionally, Clearmind obtained final regulatory approval from Hadassah Medical Center in Jerusalem to expand its Phase 1/2a clinical trial for CMND-100, furthering its multinational studies that include leading medical centers such as Yale and Johns Hopkins. The company has also engaged JS First Sdn. Bhd to source global manufacturers and distributors, supporting its international expansion plans. Furthermore, Clearmind secured $10 million in a securities purchase agreement to advance strategic opportunities and has recently filed for patents related to novel non-hallucinogenic neuroplastogen treatments for depression. Operating primarily in the biotechnology and healthcare sectors, Clearmind Medicine targets mental health and metabolic disease markets worldwide. Founded in 2017, the company is headquartered in Vancouver, Canada. It maintains a collaborative research relationship with Yissum Research Development Company of the Hebrew University of Jerusalem for developing and commercializing compounds for PTSD and other conditions. The company was formerly known as Cyntar Ventures Inc. until its name change to Clearmind Medicine Inc. in March 2021. Clearmind’s broad clinical pipeline and strategic alliances position it as an innovator in psychedelic medicine development with a focus on transforming treatment options for alcohol-related and mental health disorders.
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
Clearmind Medicine Responds to the U.S. Administration's RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment